{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "hmdb:HMDB06564",
      "entity_text" : "glucose",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:10096344",
      "entity_text" : "linagliptin",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Overall, the majority of patients with hypoglycemia were receiving insulin as monotherapy or in combination with another glucose lowering agent (s) (linagliptin, 36 [83.7%]; placebo, 27 [84.4%]).",
  "reading_complete" : "2020-07-28T14:00:00Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T13:56:59Z",
  "trigger" : "lowering",
  "evidence" : [ "glucose-lowering agent(s) (linagliptin" ],
  "pmc_id" : "3554278",
  "score" : 0
}